ClinicalTrials.gg
Not yet recruitingNCT07931950Updated Nov 12, 2026

Investigation of the Relationships Among Balance, Mobility, Pain, Fatigue, and Quality of Life in Individuals With Lyme Disease

An observational study in Lyme Disease, sponsored by Istanbul Gelisim University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Istanbul Gelisim University · Observational

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
56
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to investigate the relationships among balance, mobility, pain, fatigue, and quality of life in individuals diagnosed with Lyme disease. Lyme disease can cause various musculoskeletal and neurological symptoms that significantly impact physical function and overall well-being. In this observational study, participants will undergo clinical evaluations to assess balance performance, functional mobility levels, pain severity, fatigue levels, and health-related quality of life. The data obtained will help to better understand the clinical burden of Lyme disease and provide insight for developing targeted rehabilitation strategies.

02

Conditions studied

  • Lyme Disease

Browse trials for

Keywords

  • Lyme Borreliosis
  • Physical Therapy
  • Lyme Disease
  • Physiotherapy
03

In context

Lyme Disease

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

This study's planned enrollment of 56 is below the median of 400 across 43 observational studies indexed under Lyme Disease.

Browse Lyme Disease studies →

Lead sponsor

Istanbul Gelisim University is the lead sponsor of 65 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of adult individuals diagnosed with Lyme disease recruited from outpatient clinics and demographically matched healthy control volunteers with no history of Lyme disease or major systemic disorders.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the Lyme disease group :

  • Age between 18-65 years
  • Confirmed diagnosis of Lyme disease by a specialist physician
  • Voluntary agreement to participate in the study
  • (MMSE) score >= 24

For Healthy individuals :

  • Age between 18-65 years
  • Similar age and sex distribution to the Lyme disease patients included in the study
  • No habit of regular exercise
  • Voluntary agreement to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Presence of a cardiovascular, pulmonary, or orthopedic disease that would prevent exercising
  • Presence of a neurological disorder
  • Having experienced a symptom flare-up within the last three months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
56 participants (estimated)
Patient registry
No

Groups and cohorts

  • Lyme Disease Group

    Individuals diagnosed with Lyme disease who participate in balance, mobility, pain, fatigue, and quality of life evaluations.

  • Healthy Control Group

    Healthy control individuals with no history of Lyme disease who undergo the same evaluation protocol.

06

What researchers measure

Primary outcomes

  1. Mini-Mental State Examination (MMSE)

    Evaluates five cognitive domains: temporal/spatial orientation, registration, attention and calculation, recall, and language/visuospatial skills. Total score ranges from 0 to 30, with higher scores indicating better cognitive function (24-30: normal, 18-23: mild impairment, 0-17: severe impairment).

    Time frame: Baseline (Single evaluation at enrollment)

  2. 6-Minute Walk Test (6MWT)

    Evaluates functional exercise capacity according to American Thoracic Society (ATS) guidelines. Participants walk the maximum distance possible in 6 minutes, with total distance recorded in meters.

    Time frame: Baseline (Single evaluation at enrollment)

  3. Modified Fatigue Impact Scale (MFIS)

    Evaluates the impact of fatigue on physical, cognitive, and psychosocial functioning over the past four weeks. Contains 21 items scored on a 5-point Likert scale ranging from 0 (never) to 4 (almost always). Total score ranges from 0 to 84, with higher scores indicating a greater impact of fatigue on daily life and functioning.

    Time frame: Baseline (Single evaluation at enrollment)

  4. Fatigue Severity Scale (FSS)

    Evaluates fatigue severity and its impact on activities of daily living over the past week. Consists of 9 items rated on a 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree). The overall score is calculated as the average of the 9 item scores, ranging from 1 to 7, with higher mean scores indicating greater fatigue severity.

    Time frame: Baseline (Single evaluation at enrollment)

  5. Time Up And Go Test (TUG)

    Evaluates functional mobility and dynamic balance. Starting from a seated position in a standard-height chair, the participants stands up upon the ''start'' command, walks 3 meters at a normal walking speed, turns around a designated point, walks back, and sits down again. The time required to complete the task is recorded in seconds using a stopwatch, with shorter completion times indicating better functional mobility and dynamic balance.

    Time frame: Baseline (Single evaluation at enrollment)

  6. McGill Pain Questionnaire (MPQ)

    Evaluates pain intensity, sensory and affective qualities of pain, and its overall impact on daily life. Participants select word descriptors that best characterize their pain experience, from which the Pain Rating Index (PRI) is calculated. Higher scores indicate greater pain severity and a more significant negative impact of pain on daily life.

    Time frame: Baseline (Single evaluation at enrollment)

  7. Nottingham Health Profile (NHP)

    Evaluates health-related quality of life across 38 items covering 6 domains: energy level, pain, emotional reactions, sleep, social isolation, and physical mobility. Participants answer each item with ''yes'' or ''no'' based on their current health status. Scores are calculated separately for each domain ranging from 0 to 100, with no total composite score. Higher scores indicate greater health problems and lower quality of life in that specific domain.

    Time frame: Baseline (Single evaluation at enrollment)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 12, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jun 15, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07931950
Lead sponsor
Istanbul Gelisim University
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Gamze ARCA, PT
Contact
gamze.arca@ogr.gelisim.edu.tr
+905359389066

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion